The effects of saxagliptin on cardiac structure and function using cardiac MRI (SCARF)

ConclusionsIn this cohort of stable ambulatory patients with T2DM without heart failure, saxagliptin treatment was not associated with adverse ventricular remodeling over 6  months as assessed using CMR and biomarkers.
Source: Acta Diabetologica - Category: Endocrinology Source Type: research